Implementation of Six Sigma Methodology in Syrian Pharmaceutical Companies

Abstract

The increased competition in the global pharmaceutical market and the necessity to reach higher levels of quality of the pharmaceutical products force manufacturers to seek and adopt more effective and reliable quality management methods and techniques which allow them to introduce products with the highest possible quality level and reduced quality costs, while maintaining conformance to the pharmaceutical GMPs, technical and legislative requirements. One of the popular modern quality management methodologies is Six Sigma, which proved its high ability to increase business profits and competitiveness within more than 30 years of implementation in manufacturing and service sectors. Recently, Six Sigma methodology has been adopted by global pharmaceutical companies such as Baxter, Eli Lilly, Johnson & Johnson and Novartis and obtained considerable benefits from its abilities. This research aims at investigating the possibility to implement Six Sigma methodology in the Syrian pharmaceutical companies, and to find out what benefits a pharmaceutical company can get through the implementation of this methodology. We conducted a case study in a pharmaceutical company in Syria (Orient Pharma) in order to examine the effectiveness and advantages of Six Sigma methodology. For this purpose, a quality improvement project was conducted using DMAIC roadmap to enhance the quality for one of the main products of the company. The obtained results of DMAIC project showed an enhanced process capability, an enhanced process Sigma level, decreased variability in the process outputs. The main difficulties that have been observed during the study are resistance to change, lack of training, lack of necessary resources, attitude toward quality in the company. As a conclusion, considerable benefits can be obtained through implementing Six Sigma methodology in the Syrian pharmaceutical companies.